(KP_MAT) Number of people who inject drugs (PWID) on medication-assisted therapy (MAT) for at least 6 months within the reporting period

Export Indicator

Number of people who inject drugs (PWID) on medication-assisted therapy (MAT) for at least 6 months within the reporting period
What it measures

When proper and sufficient dosage is administered, medication-assisted therapy (MAT) is highly effective in reducing opioid use, reducing injecting behaviors that put opioiddependent people at risk for HIV and improving retention for those who are on ART. Therefore, all people who are dependent on opioids should be offered and have access to this service. The implementation of MAT programs should facilitate and enhance access to HIV-specific services for PWID, such as HIV testing services, provision and/or referral and linkages to ARV treatment programs, PMTCT for female PWID and a range of other prevention and harm reduction services.

Partners providing MAT referrals only should not use this indicator, unless it also meets the KP_MAT_TA requirement below. Please see key population indicator “KP_PREV” to see if services provided meet reporting criteria for that indicator.


Number of people who inject drugs (PWID) on medication-assisted therapy (MAT) for at least 6 months within the reporting period


Use result reported at Q4

Method of measurement

This indicator provides information on the total number of individuals who have been on treatment for at least 6 months since initiation of medication-assisted treatment (e.g. methadone, buprenorphine, or buprenorphine/naloxone to treat drug dependency) at any point in time within the reporting period. Therefore data for this indicator can be generated by counting the number of individuals who are currently receiving MAT or received at least 6 months of MAT in the reporting period in accordance with the nationally approved treatment protocol (or WHO/UNAIDS standards) at the end of the reporting period.

Count all individuals who complete at least 6 months of treatment even if they drop-out, die, or are otherwise lost to follow-up, as long as they completed the minimum of 6 months treatment. Do not count individuals who initiate treatment too late in the reporting period to be able to reach a minimum of 6 months.

How to review for data quality

This indicator makes use of program data as part of an on-going cohort, similar to that used to monitor ART retention. MAT register and/or patient-level data can be used to determine the number of people starting MAT in the defined period, as a cohort, and the number of those who are still in treatment 6 months after starting MAT.

Data should be reviewed regularly for the purposes of program management, to monitor progress towards achieving targets, and to identify and correct any data quality issues.

Reporting Level

Site level: facility

Measurement frequency



Numerator: Number of people who inject drugs (PWID) on MAT for at least six months within the reporting period


Male; Female

Further information

MER 1.0 to 2.0 Change

No change in definition from MER 1.0 to 2.0

PEPFAR Support definition

Standard definition of DSD and TA-SDI used:

Provision of key staff or commodities for PWID on MAT includes: procurement of methadone or any other medication assisted options for the treatment of opioid dependence, or funding for salaries of personnel delivering the service (i.e., HCW, program managers). Staff who are responsible for the completeness and quality of routine patient records (paper or electronic) can be counted here; however, staff who exclusively fulfill MOH and donor reporting requirements cannot be counted.

Ongoing support for MAT services for PWID service delivery improvement includes: mentoring and supportive supervision, training, MAT guidance development, site level QA/QI, regular assistance with monitoring and evaluation functions and data quality assessments, or MAT consumption forecasting and supply management.